Silicon Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

silicontx.com

Stage

Acquired | Acquired

Total Raised

$6.5M

Valuation

$0000 

About Silicon Therapeutics

Silicon Therapeutic (STX) aims to design novel therapeutics for the advancement of human health by building the most accurate in silico models of highly implicated human drug targets. STX has developed its own proprietary In Silico Targeted Engineering (INSITE) platform around this goal. Currently, the company is applying the INSITE platform against target proteins that experience significant conformational change, which often renders them inaccessible to traditional drug discovery methods. STX plans to maintain scientific leadership in the field by first continuing to improve the science behind the INSITE platform, in addition to applying the INSITE platform to drive STX's pipeline toward the clinic.On February 26th, 2021, Silicon Therapeutics was acquired by Roivant Sciences at a valuation of $450M.

Silicon Therapeutics Headquarter Location

300 A Street

Boston, Massachusetts, 02110,

United States

617-937-2300

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Silicon Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Silicon Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Latest Silicon Therapeutics News

20:46 EDT Harbour BioMed Appoints Dr. Humphrey Gardner as Chief Medical Officer

Apr 14, 2022

News provided by Share this article Share this article CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2022 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), today announced the appointment of Dr. Humphrey Gardner as Chief Medical Officer (CMO). Dr. Gardner will be responsible for leading the global product development of the Company, including pipeline strategy, clinical development plan and operations, and product registration. Dr. Gardner has more than 30 years industry experience, achievement and leadership in clinical development and translational medicine, including over 20 years of experience in the pharmaceutical industry and over 10 years of experience in academia. Before joining the Company, he served as the chief medical officer at Silicon Therapeutics and the chief of medical oncology at Evelo Biosciences. He also served critical leadership roles at Novartis, AstraZeneca and Biogen. "I am delighted to welcome Dr. Gardner, an industry veteran and highly respected scientist, to Harbour BioMed. Dr. Gardner's extensive experience in drug development from conception to approval will be instrumental to advancing our innovative therapeutics through global clinical trials and on to registration," said Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer. "He is joining HBM at a very important time and will be a tremendous asset to our organization, strengthening our mission to deliver breakthrough medicines for healthy life." With Dr. Gardner's appointment, the Company will further strengthen its global clinical development capability and continue to advance the global development of its clinical products, including next-generation anti-CTLA-4 antibody HBM4003 and B7H4x4-1BB bispecific antibody HBM7008, whilst enriching the pipeline strategy of the global development of its immune-oncology pipeline. "I am profoundly excited to bring my experience to HBM, an organization I have long admired," said Dr. Gardner. "I am looking forward to working with the Company's talented teams to advance novel and highly innovative antibody-based therapeutics in the areas of oncology and immunological diseases and to build a robust pipeline that has the opportunity to transform care for many more patients in need around the world." Dr. Gardner holds a bachelor's degree in Biochemistry and his medical degree from the University of Cambridge, and an MS in Bioinformatics from Brandeis University. He completed his residency in Anatomic Pathology at Beth Israel Hospital, Harvard Medical School, and postdoctoral training at Whitehead Institute, Massachusetts Institute of Technology (MIT). Dr. Gardner is an expert in oncology, rheumatology, and infectious disease. He published approximately one hundred papers in international academic journals, and has been an active influential speaker at international conferences. He is also a fellow of the College of American Pathologists, and a member of American Society of Clinical Oncology, and has previously been a member of a variety of professional organizations including the European Society of Clinical Microbiology and Infectious Diseases and the American Association for Clinical Chemistry. About Harbour BioMed Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners and select acquisitions. The Company's proprietary antibody technology platforms Harbour Mice® generate fully human monoclonal antibodies in two heavy and two light chain (H2L2) format, as well as heavy chain only (HCAb) format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) are capable of delivering tumor killing effects unachievable by traditional combination therapies. Integrating Harbour Mice® with single B cell cloning platform, our antibody discovery engine is highly unique and efficient for development of next generation therapeutic antibodies. SOURCE Harbour BioMed

  • Where is Silicon Therapeutics's headquarters?

    Silicon Therapeutics's headquarters is located at 300 A Street, Boston.

  • What is Silicon Therapeutics's latest funding round?

    Silicon Therapeutics's latest funding round is Acquired.

  • How much did Silicon Therapeutics raise?

    Silicon Therapeutics raised a total of $6.5M.

  • Who are Silicon Therapeutics's competitors?

    Competitors of Silicon Therapeutics include Redesign Science.

You May Also Like

XtalPi Logo
XtalPi

XtalPi is a cloud-based technology company that solves drug polymorphism by providing accurate computational crystal structure prediction for small-molecule drugs.

Atomwise Logo
Atomwise

Atomwise uses deep learning neural networks to help discover new medicines. Atomwise achieves results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, start-ups, and research institutions. It is currently using computational drug design to design drugs against COVID.

Acellera Logo
Acellera

Acellera is a computational drug discovery company that develops ACEMD, a solution for building, simulating, and analyzing molecular systems, and PlayMolecule, a platform that offers molecular dynamics and machine learning applications for drug discovery with a specific focus on drug design.

Redesign Science Logo
Redesign Science

Redesign Science is a computational chemistry company that engages in early-stage, small molecule drug discovery. The company efficiently simulates protein targets at the atomic level to reveal hidden, subtle drug opportunities that fall outside the capability, and scope of alternative computational models.

Roivant Sciences Logo
Roivant Sciences

Roivant Sciences (NASDAQ: ROIV) focuses on developing and commercializing therapies through wholly- or majority-owned subsidiary companies including, Axovant, Myovant, Dermavant, Enzyvant, and Urovant.

Relay Therapeutics Logo
Relay Therapeutics

Relay Therapeutics (NASDAQ: RLAY) combines computational skills with experimental approaches across the fields of structural biology, biophysics, chemistry and biology. The integration of these disparate disciplines, tools, and cultures enables the company to design therapies against validated but previously intractable targets. Its initial discovery programs in cancer have led to the development of highly selective inhibitors of disease-causing proteins in genomically defined patient populations.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.